Search
for
Sort by
Research 30 of 1000+
- A Novel Effect of Acyclovir on Hair Growth in BALB/c Mice: A Promising Future for Finding a New Topical Drug for the Treatment of Hirsutism
- A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers
- The use of biodegradable microneedle patches to increase penetration of topical steroid for prurigo nodularis.
- A novel microparticle based formulation for topical delivery of FOL-005, a small peptide
- Sinus Node Dysfunction in a Child After Developed by the Use of Topical Minoxidil
- Acquired Trichorrhexis Nodosa Caused by Massage of the Scalp After Topical Minoxidil: A Case Report and Review of the Literature
- Clinical Efficacy, Cosmetic Acceptability, and Local Tolerability of a New Formulation of Topical 5% Minoxidil without Propylene glycol: A 6-month, Multicentre, Real-life, Prospective, Assessor-Blinded Study in 196 Subjects with Hair Loss. The andldquo;NOMINALandrdquo; Trial
- The “NOMINAL” trial: Clinical efficacy, cosmetic acceptability, and local tolerability of topical 5% minoxidil lotion without propylene glycol: A 6-month, multicentre, real-life, prospective, assessor-blinded study in 196 subjects with hair loss.
- A NOVEL NANOGEL FORMULATION OF FINASTERIDE FOR TOPICAL TREATMENT OF ANDROGENETIC ALOPECIA: DESIGN, CHARACTERIZATION AND IN VITRO EVALUATION
- Topical Administration of 15‐Deoxy‐<i>Δ</i><sup>12,14</sup>‐Prostaglandin J<sub>2</sub> Using a Nonionic Cream: Effect on UVB‐Induced Skin Oxidative, Inflammatory, and Histopathological Modifications in Mice
- Novel “After Minoxidil” spray improves topical minoxidil compliance and hair style manageability
- Treatment of alopecia areata with nonablative fractional laser combined with topical minoxidil
- Could Topical Minoxidil Cause Non-Arteritic Anterior Ischemic Optic Neuropathy?
- The Efficacy of Topical Minoxidil for Non-Scarring Alopecia: A Systematic Review
- Prospective Evaluation of Topical Minoxidil in Non-Segmental Vitiligo .
- Fast clinical response with topical ruxolitinib in the management of non-segmental vitiligo detected by VISIA<sup>®</sup> analysis system
- Topical Treatment for Scarring and Non-Scarring Alopecia: An Overview of the Current Evidence
- Novel iron oxide nanocarriers loading finasteride or dutasteride: Enhanced skin penetration for topical treatment of alopecia
- Novel topical booster enhances follicular sulfotransferase activity in patients with androgenetic alopecia: a new strategy to improve minoxidil response
- Emulgel: A Novel Strategy for Enhanced the Topical Drug Delivery
- Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
- Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
- Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
- Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
- Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
- Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
- Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
- Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
- Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
- Novel Dual Soft Drug Strategy Enables Development of Topical Androgen Receptor Antagonists with Enhanced Efficacy and Optimized Safety for Androgenetic Alopecia